Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -2.5.EBIT: As of FY2025 Q3, the actual value is USD -1.753 M.<h3>Segment Revenue</h3><ul><li>No product revenue was reported for the three and nine months ended September 30, 2025 and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss was $2,811,388, compared to $1,929,391 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $5,732,326, compared to $21,295,080 for the same period in 2024.</li><li>General and Administrative Expenses: $967,833 for the three months ended September 30, 2025, compared to $1,104,130 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $2,703,815, compared to $3,149,041 for the same period in 2024.</li><li>Research and Development Expenses: $356,352 for the three months ended September 30, 2025, compared to $707,747 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $2,775,337, compared to $2,307,789 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $5,865,877 for the nine months ended September 30, 2025, compared to $6,855,523 for the same period in 2024.</li><li>Investing Cash Flow: Net cash provided by investing activities was $3,245,029 for the nine months ended September 30, 2025, compared to net cash used of $7,202,955 for the same period in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities was $9,351,879 for the nine months ended September 30, 2025, compared to $13,926,528 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Derivative Liabilities: The change in fair value of derivative liabilities resulted in a gain of $244,000 for the nine months ended September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company has shifted its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. This includes leveraging an exclusive global licensing agreement with LightSolver Ltd. to deploy innovative laser processing units (LPUs).</li><li>Non-Core Business: The company is evaluating the potential divestiture of its Isomyosamine and Supera-CBD therapeutic platforms to fund its new strategic focus.</li><li>Priority: Over the next twelve months, the company anticipates finalizing qc-LPU100 prototypes, conducting internal performance benchmarking, securing patents, and initiating pilot testing with select AI and DePin Token users.</li></ul>

Q/C Tech | 10-Q: FY2025 Q3 Revenue: USD 0